<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30304013</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1932-6203</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>13</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>PloS one</Title>                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>            </Journal>            <ArticleTitle>Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.</ArticleTitle>            <Pagination>                <MedlinePgn>e0204973</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0204973</ELocationID>            <Abstract>                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Onapristone is a type I progesterone receptor (PR) antagonist, which prevents PR- mediated DNA transcription. Onapristone is active in multiple preclinical models and two prior studies demonstrated promising activity in patients with breast cancer. We conducted a study of extended release (ER) Onapristone to determine a recommended dose and explore the role of transcriptionally-activated PR (APR), detected as an aggregated subnuclear distribution pattern, as a predictive biomarker.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">An open-label, multicenter, randomized, parallel-group, phase 1 study (target n = 60; NCT02052128) included female patients ≥18 years with PRpos tumors. APR analysis was performed on archival tumor tissue. Patients were randomized to five cohorts of extended release (ER) onapristone tablets 10, 20, 30, 40 or 50 mg BID, or immediate release 100 mg QD until progressive disease or intolerability. Primary endpoint was to identify the recommended phase 2 dose. Secondary endpoints included safety, clinical benefit and pharmacokinetics.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The phase 1 dose escalation component of the study is complete (n = 52). Tumor diagnosis included: endometrial carcinoma 12; breast cancer 20; ovarian cancer 13; other 7. Median age was 64 (36-84). No dose limiting toxicity was observed with reported liver function test elevation related only to liver metastases. The RP2D was 50 mg ER BID. Median therapy duration was 8 weeks (range 2-44), and 9 patients had clinical benefit ≥24 weeks, including 2 patients with APRpos endometrial carcinoma.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Clinical benefit with excellent tolerance was seen in heavily pretreated patients with endometrial, ovarian and breast cancer. The data support the development of Onapristone in endometrial endometrioid cancer. Onapristone should also be evaluated in ovarian and breast cancers along with APR immunohistochemistry validation.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Cottu</LastName>                    <ForeName>Paul H</ForeName>                    <Initials>PH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut Curie, Paris, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bonneterre</LastName>                    <ForeName>Jacques</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Centre Oscar Lambret, Lille, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Varga</LastName>                    <ForeName>Andrea</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Gustave Roussy, Villejuif, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Campone</LastName>                    <ForeName>Mario</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Nantes, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Leary</LastName>                    <ForeName>Alexandra</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Gustave Roussy, Villejuif, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Floquet</LastName>                    <ForeName>Anne</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut Bergonié, Bordeaux, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Berton-Rigaud</LastName>                    <ForeName>Dominique</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Nantes, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sablin</LastName>                    <ForeName>Marie-Paule</ForeName>                    <Initials>MP</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut Curie, Paris, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lesoin</LastName>                    <ForeName>Anne</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Centre Oscar Lambret, Lille, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rezai</LastName>                    <ForeName>Keyvan</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Centre Rene Huguenin-Institut Curie, St Cloud, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lokiec</LastName>                    <ForeName>François M</ForeName>                    <Initials>FM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Centre Rene Huguenin-Institut Curie, St Cloud, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lhomme</LastName>                    <ForeName>Catherine</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Gustave Roussy, Villejuif, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bosq</LastName>                    <ForeName>Jacques</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Gustave Roussy, Villejuif, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bexon</LastName>                    <ForeName>Alice S</ForeName>                    <Initials>AS</Initials>                    <AffiliationInfo>                        <Affiliation>Bexon Clinical Consulting, Upper Montclair, NJ, United States of America.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gilles</LastName>                    <ForeName>Erard M</ForeName>                    <Initials>EM</Initials>                    <AffiliationInfo>                        <Affiliation>Invivis Pharmaceuticals, Bridgewater, NJ, United States of America.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Proniuk</LastName>                    <ForeName>Stefan</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Arno Therapeutics, Flemington, NJ, United States of America.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dieras</LastName>                    <ForeName>Veronique</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut Curie, Paris, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jackson</LastName>                    <ForeName>David M</ForeName>                    <Initials>DM</Initials>                    <AffiliationInfo>                        <Affiliation>Arno Therapeutics, Flemington, NJ, United States of America.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zukiwski</LastName>                    <ForeName>Alexander</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Arno Therapeutics, Flemington, NJ, United States of America.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Italiano</LastName>                    <ForeName>Antoine</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut Bergonié, Bordeaux, France.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>PLoS One</MedlineTA>            <NlmUniqueID>101285081</NlmUniqueID>            <ISSNLinking>1932-6203</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>BJU Int. 2008 May;101(9):1084-9</RefSource>                <PMID Version="1">18399827</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Reprod. 1996 Jan;11(1):40-9</RefSource>                <PMID Version="1">8671154</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Steroids. 2000 Oct-Nov;65(10-11):825-30</RefSource>                <PMID Version="1">11108894</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 1996 Jan 12;271(2):1209-17</RefSource>                <PMID Version="1">8557652</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Opin Pharmacother. 2014 Jul;15(10):1403-15</RefSource>                <PMID Version="1">24787486</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 1999 Feb;35(2):214-8</RefSource>                <PMID Version="1">10448262</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2015 Jul 16;523(7560):313-7</RefSource>                <PMID Version="1">26153859</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Prostate. 2001 Sep 15;48(4):285-91</RefSource>                <PMID Version="1">11536308</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Obstet Gynecol. 2007 Feb;109(2 Pt2):512-4</RefSource>                <PMID Version="1">17267877</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Steroids. 2000 Oct-Nov;65(10-11):795-800</RefSource>                <PMID Version="1">11108890</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Endocrinol Metab. 2004 Mar;89(3):1429-42</RefSource>                <PMID Version="1">15001645</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ernst Schering Found Symp Proc. 2007;(1):77-107</RefSource>                <PMID Version="1">18540569</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocr Relat Cancer. 2012 May 03;19(3):R35-50</RefSource>                <PMID Version="1">22351709</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Steroid Biochem Mol Biol. 2009 Jan;113(1-2):105-15</RefSource>                <PMID Version="1">19130882</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Reproduction. 2015 Jan;149(1):R15-33</RefSource>                <PMID Version="1">25252652</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2005 Jul 15;65(14):6450-8</RefSource>                <PMID Version="1">16024650</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Clin Pathol. 2005 Jan;123(1):21-7</RefSource>                <PMID Version="1">15762276</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Steroids. 2003 Nov;68(10-13):1053-9</RefSource>                <PMID Version="1">14667998</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Annu Rev Physiol. 2007;69:171-99</RefSource>                <PMID Version="1">17037979</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2010 Feb 15;70(4):1722-30</RefSource>                <PMID Version="1">20124487</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Fertil Steril. 2003 Feb;79(2):386-92</RefSource>                <PMID Version="1">12568850</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2013 Oct;24(10):2543-8</RefSource>                <PMID Version="1">23788750</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Reprod. 1994 Aug;9(8):1442-7</RefSource>                <PMID Version="1">7989502</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2002 Mar;72(2):163-72</RefSource>                <PMID Version="1">12038707</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2013 Aug;14(9):853-62</RefSource>                <PMID Version="1">23845225</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gynecol Oncol. 2015 Sep;138(3):663-7</RefSource>                <PMID Version="1">26142884</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nucleic Acids Res. 1991 Mar 25;19(6):1227-34</RefSource>                <PMID Version="1">2030942</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pathol Res Pract. 1993 Nov;189(9):1015-22</RefSource>                <PMID Version="1">8302719</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 1999 Jun;17(6):1736-44</RefSource>                <PMID Version="1">10561210</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2015 Jul 1;33(19):2221-5</RefSource>                <PMID Version="1">25940721</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 1984 Jan 1;53(1):113-6</RefSource>                <PMID Version="1">6689993</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Exp Med Biol. 2008;630:94-111</RefSource>                <PMID Version="1">18637487</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocr Rev. 2013 Feb;34(1):130-62</RefSource>                <PMID Version="1">23303565</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <CoiStatement>Jacques Bonneterre is a consultant to Arno Therapeutics and Invivis Pharmaceuticals. Keyvan Rezai, François Lokiec, Jacques Bosq, and Alice S Bexon are consultants to Arno Therapeutics. Erard M Gilles is an employee of Invivis Pharmaceuticals and consultant to Arno Therapeutics. Stefan Proniuk and David M. Jackson are employees and stock owners of Arno Therapeutics. Alexander Zukiwski is CEO and stock owner of Arno Therapeutics. Paul H Cottu, Andrea Varga, Mario Campone, Alexandra Leary, Anne Floquet, Dominique Berton-Rigaud, Marie-Paule Sablin, Anne Lesoin, Catherine Lhomme, Veronique Dieras, and Antoine Italiano have no relevant conflicts of interest to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>07</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>03</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30304013</ArticleId>            <ArticleId IdType="doi">10.1371/journal.pone.0204973</ArticleId>            <ArticleId IdType="pii">PONE-D-17-25400</ArticleId>            <ArticleId IdType="pmc">PMC6179222</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>